Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or OpenAthens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Novel Insights from Clinical Practice

Corneal Myofibroma (Keloid) in a Young Patient with Neurofibromatosis Type 2

Zimmermann L.a · Reinhard T.a · Lange C.a · Heegaard S.b · Auw-Haedrich C.a

Author affiliations

aEye Center, Albert-Ludwigs-University, Freiburg, Germany; bPathology Department, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark

Related Articles for ""

Ocul Oncol Pathol 2017;3:247-249

Do you have an account?

Login Information





Contact Information











I have read the Karger Terms and Conditions and agree.



Login Information





Contact Information











I have read the Karger Terms and Conditions and agree.



To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.
Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00


Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Novel Insights from Clinical Practice

Received: June 02, 2016
Accepted: January 25, 2017
Published online: March 22, 2017
Issue release date: November 2017

Number of Print Pages: 3
Number of Figures: 4
Number of Tables: 0

ISSN: 2296-4681 (Print)
eISSN: 2296-4657 (Online)

For additional information: https://www.karger.com/OOP

Abstract

We present a 27-year-old male patient with neurofibromatosis type 2 (NF2), facial palsy, and lagophthalmos following acoustic neuroma removal and an impressing vascularized corneal tumor, which was excised. Histology showed a fibrous tumor with small vessels, and immunohistochemistry was positive for vimentin and negative for smooth muscle actin, S100, and GFAP. We assume a corneal myofibroma (keloid), which in this case rather represents a reactive lesion. This entity has not been described before in NF2 or in facial palsy-associated lagophthalmos in general.

© 2017 S. Karger AG, Basel


References

  1. Evans DGR: Neurofibromatosis type 2 (NF2): a clinical and molecular review. Orphanet J Rare Dis 2009;4:16.
  2. Parry DM, Eldridge R, Kaiser-Kupfer MI, et al: Neurofibromatosis 2 (NF2): clinical characteristics of 63 affected individuals and clinical evidence for heterogeneity. Am J Med Genet 1994;52:450-461.
  3. McLaughlin ME, Pepin SM, Maccollin M, et al: Ocular pathologic findings of neurofibromatosis type 2. Arch Ophthalmol 2007;125:389-394.
  4. Bouzas EA, Freidlin V, Parry DM, et al: Lens opacities in neurofibromatosis 2: further significant correlations. Br J Ophthalmol 1993;77:354-357.
  5. Holbach LM, Font RL, Shivitz IA, Jones DB: Bilateral keloid-like myofibroblastic proliferations of the cornea in children. Ophthalmology 1990;97:1188-1193.

Article / Publication Details

First-Page Preview
Abstract of Novel Insights from Clinical Practice

Received: June 02, 2016
Accepted: January 25, 2017
Published online: March 22, 2017
Issue release date: November 2017

Number of Print Pages: 3
Number of Figures: 4
Number of Tables: 0

ISSN: 2296-4681 (Print)
eISSN: 2296-4657 (Online)

For additional information: https://www.karger.com/OOP


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.